Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.653 USD | +2.08% | +0.45% | -12.42% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Business Summary
Number of employees: 18
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncology Therapeutics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Victor Moyo
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Matthew Parris
CTO | Chief Tech/Sci/R&D Officer | - | 18-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Trafford Clarke
BRD | Director/Board Member | 66 | 22-12-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 25,301,009 | 21,604,002 ( 85.39 %) | 0 | 85.39 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.42% | 13.49M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- TRAW Stock
- Company Traws Pharma, Inc.